First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
Alexander Starodub(Dana-Farber Cancer Institute), David M. Goldenberg(Unknown), William A. Wegener(Children's Hospital of Philadelphia), Vincent J. Picozzi(Virginia Mason Medical Center), Robert M. Sharkey(Immunomedics (United States)), Serengulam V. Govindan(Dana-Farber Cancer Institute), Allyson J. Ocean(Dana-Farber Cancer Institute), Linda T. Vahdat(Dartmouth–Hitchcock Medical Center), Sajeve Thomas(Orlando Health), Pius Maliakal(Dana-Farber Cancer Institute), Manish A. Shah(NewYork–Presbyterian Hospital), Steven A. Hamburger(Immunomedics (United States)), Michael J. Guarino(Dana-Farber Cancer Institute)
Cited by 344
Related Papers
Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance
|Nature|2015|1.8k
Connecting copper and cancer: from transition metal signalling to metalloplasia
|Nature reviews. Cancer|2021|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
|The Lancet|2011|1.1k
Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry
|Journal of Clinical Oncology|2005|1.1k